Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.

ABSTRACT:

Background & aims

Changes in gut microbiota in metabolic dysfunction-associated steatotic liver disease (MASLD) are important drivers of disease progression towards fibrosis. Therefore, reversing microbial alterations could ameliorate MASLD progression. Oat beta-glucan, a non-digestible polysaccharide, has shown promising therapeutic effects on hyperlipidemia associated with MASLD, but its impact on gut microbiota and most importantly MASLD-related fibrosis remains unknown.

Methods

We performed detailed metabolic phenotyping, including assessments of body composition, glucose tolerance, and lipid metabolism, as well as comprehensive characterization of the gut-liver axis in a western-style diet (WSD)-induced model of MASLD and assessed the effect of a beta-glucan interventio

SUBMITTER: Jaeger JW 

PROVIDER: S-EPMC10844974 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature